45-Gy EQD2 elective nodal irradiation maintained 97% regional control in nasopharyngeal cancer
In 752 NPC patients, 45-Gy EQD2 elective nodal irradiation achieved 97.3% 5-year regional control with only 0.7% elective-volume failures.
In 752 NPC patients, 45-Gy EQD2 elective nodal irradiation achieved 97.3% 5-year regional control with only 0.7% elective-volume failures.
ROAM/EORTC-1308 improved 5-year disease-free survival from 64.3% to 79.9% after complete resection of WHO grade 2 meningioma.
In advanced differentiated thyroid cancer, IMRT/VMAT was associated with a 61% lower hazard of locoregional relapse or death.
Only 21% started PORT within 42 days after laryngectomy, while each additional week of delay was associated with 3.7% higher mortality.
After a national audit triggered pathway redesign, severe late GI toxicity after prostate EBRT fell from 16% to 7.5%.
After matching 530 patients, CTV omission preserved survival and recurrence patterns while substantially reducing pneumonitis and esophagitis.
ITV underdosage occurred in 21% of distal esophageal IMPT patients, yet no GTV underdosage occurred and tumor response was unchanged.
In 331 Danish NPC patients, five-year failure rates were similar by EBV status, while distant relapse was concentrated in locally advanced disease.
Patients aged ≥70 reported similar or lower symptom burden, whereas PS ≥2 consistently predicted worse toxicity and slower recovery after radical RT.
In 223 previously irradiated patients, 3×10 Gy and 2×13 Gy salvage HDR brachytherapy produced similar disease control and late toxicity.
In a prospective proton registry enriched for ultracentral, large, and re-irradiated lung tumors, two-year local control was 77% with no grade ≥3 toxicity.
PET-directed elective nodal RT plus temporary ADT yielded 77% 10-year overall survival with low grade 3 GU and GI toxicity.
ASTRO recommends trimodal therapy as an alternative to cystectomy in selected muscle-invasive bladder cancer and supports 55 Gy in 20 fractions.
Surgery provided substantially better local control in T3–T4a N0–N1 laryngeal cancer, while disease-specific survival remained similar and CRT preserved laryngeal function in 79%.
HYPO-RT-PC showed persistently poor agreement between patient- and clinician-reported toxicity, particularly for urinary and bowel symptoms.